Penn Center for Myeloproliferative Neoplasms

Elizabeth Olson Hexner

faculty photo

Elizabeth Olson Hexner

Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-151
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-1847
Fax: 215-615-5888
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Genetically modified T Cell Therapies
CAR T cells
Cellular therapy
Blood and Marrow Transplantation
Myeloproliferative Neoplasms
Umbilical Cord Blood Transplantation

Selected Publications

Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplant Cell Ther Dec 2023.

Hexner EO. : The splendor and the tyranny of JAK inhibition. Haematologica Dec 2023.

Zev Binder, Stephen J Bagley, Lamia Lamrani, Eliana Marinari, Arati Desai, MacLean P Nasrallah, Eileen Maloney, Steven Brem, Robert A Lustig, Goldie Kurtz, Michelle Alonso-Basanta, Pierre-Emmanuel Bonte, Christel Goudot, Wilfrid Richer, Eliane Piaggio, Shawn Kothari, Lea Guyonnet, Coralie Guerin, Joshua Waterfall, Suyash Mohan, Wei-Ting Hwang, Oliver Tang, Meghan Logun, Meghna Bhattacharyya, Kelly Markowitz, Devora Delman, Amy Marshall, E John Wherry, Sebastian Amigorena, Gregory Beatty, Jennifer Brogdon, Elizabeth Hexner, Denis Migliorini, Cecile Alanio, Donald M O'Rourke: CTIM-24. REPEATED PERIPHERAL INFUSIONS OF ANTI-EGFRVIII CAR T CELLS IN COMBINATION WITH PEMBROLIZUMAB REMODELS THE TUMOR MICROENVIRONMENT IN DE NOVO GLIOBLASTOMA. Neuro-Oncology Nov 2023.

EO Hexner: Hematopoietic Stem Cell Transplant (HSCT) Fact Sheet for Healthcare Professionals. The Leukemia & Lymphoma Society Oct 2023.

Wang Y, He S, Calendo G, Bui T, Tian Y, Lee CY, Zhou Y, Zhao X, Abraham C, Mo W, Chen M, Sanders-Braggs R, Madzo J, Issa JJ, Hexner EO, Wiest DL, Reshef R, Xue HH, Zhang Y.: Tissue-infiltrating Alloreactive T Cells Require Id3 to Deflect PD-1-mediated Immune Suppression during GVHD. Blood Oct 2023.

Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. Aug 2023.

Chippendale L, Freyer CW, Carulli A, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, Porter DL, Stadtmauer EA, Loren AW.: One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant. J Oncol Pharm Pract Aug 2023.

Akahoshi Y, Spyrou N, Hogan WJ, Ayuk FA, DeFilipp Z, Weber D, Choe HK, Hexner EO, Rösler W, Etra AM, Sandhu KS, Yanik GA, Chanswangphuwana C, Kitko CL, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp SA, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine JE, Ferrara JLM, Chen YB: Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Adv. Jun 2023.

Ren JG, Xing B, Lv K, O'Keefe RA, Wu M, Wang R, Bauer KM, Ghazaryan A, Burslem GM, Zhang J, O'Connell RM, Pillai V, Hexner EO, Philips MR, Tong W: RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia. J Clin Invest Jun 2023.

Al Malki MM, London K, Baez J, Akahoshi Y, Hogan WJ, Etra AM, Choe HK, Hexner EO, Langston A, Abhyankar SH, Ponce DM, DeFilipp Z, Kitko CL, Adekola KUA, Reshef R, Ayuk FA, Capellini A, Chanswangphuwana C, Eder M, Eng GW, Gandhi I, Grupp SA, Gleich S, Holler E, Javorniczky NR, Kasikis S, Kowalyk S, Morales G, Özbek U, Rösler W, Spyrou N, Young R, Yanik GA, Chen YB: Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Adv. May 2023.

back to top
Last updated: 12/14/2023
The Trustees of the University of Pennsylvania
 

The Penn Difference

  • Individualized Treatment Plan
  • Expert Treatment Team Knowledgeable in Myeloproliferative Disorders
  • State-of-the-Art Personalized Diagnostic Testing
  • Access to Newest Therapies Through Clinical Trials
  • Comprehensive Bone Marrow Transplantation Service
  • Integrated Care by a Multidisciplinary Treatment Team

Make an Appointment

New Patients:
Abramson Cancer Center
Perelman Center for Advanced Medicine
2nd Floor, West Pavilion
Philadelphia, PA 19104
Phone: 215-615-5858 option 2
Fax: 215-615-5889

Current Patients:
Contact your doctor directly

For General Inquiries:
Call the Myeloproliferative Neoplasms Program at  215-614-1847


Donate


Search